편도암의 근치적 치료 결과

Results of Curative Treatment for Cancer of the Tonsil

  • 박원 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 안용찬 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 임도훈 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 백정환 (성균관대학교 의과대학 삼성서울병원 이비인후과) ;
  • 손영익 (성균관대학교 의과대학 삼성서울병원 이비인후과) ;
  • 박근칠 (성균관대학교 의과대학 삼성서울병원 혈액종양내과) ;
  • 김경주 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 이정은 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 강민규 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 박영제 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 남희림 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 허승재 (성균관대학교 의과대학 삼성서울병원 방사선종양학과)
  • Park, Won (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ahn, Yong-Chan (Department of Radiation Oncology, Samsung Medical Center) ;
  • Lim, Do-Hoon (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Baek, Chung-Whan (Department of Otorhinolaryngology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Son, Young-Ik (Department of Otorhinolaryngology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Keun-Chil (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Kyoung-Ju (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Jeung-Eun (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kang, Min-Kyu (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Young-Je (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Nam, Hee-Rim (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Huh, Seung-Jae (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 발행 : 2003.12.01

초록

목적: 편도암으로 진단받고 근치적 목적의 치료를 시행받은 환자들의 치료성적을 후향적으로 분석하여 그 결과를 보고하고자 하였다. 대상 및 방법: 1995년 1월부터 2000년 12월까지 삼성서울병원에서 편도의 편평상피세포암으로 진단받고 근치적 목적의 치료가 시행된 27례를 대상으로 하였다. 대상환자들에 대한 국소치료법의 결정은 두경부 종양 협진팀에서 합의하여 결정하였으며, 방사선치료를 우선적으로 고려하였던 기준은 (1) 환자측 요인으로 전신마취와 수술의 위험이 큰 경우, (2) 환자의 수술 거부, (3) 근치적 수술절제가 여의치 않거나, (4) 수술 후 기능장애가 클 것으로 예견된 경우 등이었다. 국소치료법으로 수술을 우선적으로 시행하고 수술 후 방사선치료를 선별적으로 추가한 경우가 17명이었고(S$\pm$RT군), 근치적 방사선치료 단독 혹은 동시병용 방사선-항암화학요법을 시행한 경우가 10명이었다(RT$\pm$CT군). 대상 환자들에 대한 추적관찰기간은 3$\~$94 (중앙값 41)개월이었다. 결과: AJCC 병기는 I$\~$II병기가 4명, III병기가 2명, IV병기가 21명이었다. 전체 환자의 5년 무병생존율은 73.3$\%$ 였고, 5$\pm$RT군과 RT$\pm$CT군 각각 70.6$\%$와 77.8$\%$였다. 관찰기간 중 모두 7명에서 재발이 발현하였으며, 이들은 모두 III$\~$IV병기 환자들이었고 치료개시 후 2년 이내에 재발하였다. S$\pm$RT군에서는 국소재발 2명, 영역재발 2명, 원격전이 1명을 포함하여 모두 5명이 재발하였고(조재발률=29.4$\%$), RT$\pm$CT군에서는 국소+영역재발 1명, 원격전이 1명을 포함하여 2명이 재발하였다(조재발률=20$\%$). 전체 환자의 5년 생존율은 77.0$\%$였고, S$\pm$RT군과 RT$\pm$CT군별로는 각각 80.9$\%$와 70.0$\%$였다. 결론: 저자들은 편도암에 대한 국소치료법으로서 수술을 주로 적용한 경우와 방사선치료를 주로 적용한 경우 모두에서 다른 문헌들에서 보고되는 국소제어율, 생존율과 비슷한 수준의 비교적 좋은 치료결과를 얻을 수 있었다. 국소적으로 진행된 편도암에서 방사선치료를 근간으로 하는 치료법은 수술에 의한 기능장애를 피할 수 있는 대안으로 판단된다.

Purpose: To report the results of curative treatment for patients with tonsil cancer by retrospective analysis. Materials and Methods: From Jan. 1995 till Dec. 2000, 27 patients with squamous cell carcinoma of the tonsil received curative treatment at Samsung Medical Center. Therapeutic decision was made through multidisciplinary conference, and curative radiation therapy was favored when, (1) the patient's condition was not fit for general anesthesia and surgery, (2) the patient refused surgery, (3) complete resection was presumed impossible, or (4) too severe disability was expected after surgery. Surgery was the main local modality in 17 patients (S$\pm$RT group), and radiation therapy in 10 (RT$\pm$CT group). The median follow-up period was 41 months. Results: AJCC stages were I/II in four, III in two, and IV in 21 patients. The 5-year disease-free survival rate was 73.3$\%$ in all patients, 70.6$\%$ in the S$\pm$RT group, and 77.8$\%$ in the RT$\pm$CT group. Treatment failure occurred in seven patients, all with stage III/IV, and all the failures occurred within 24 months of the start of treatment. Five patients among the S$\pm$CT group developed treatment failures; 2 local, 2 regional, and 1 distant (crude rate=29.4$\%$). Two patients among the RT$\pm$CT group developed failures; 1 synchronous local and regional, and 1 distant (crude rate=20.0$\%$). The 5-year overall survival rate was 77.0$\%$ in all patients, 80.9$\%$ in the S$\pm$RT group, and 70.0$\%$ in the RT$\pm$CT group. Conclusion: We could achieve favorable results that were comparable to previously reported data with respect to both the rates of local control and of survival by applying S$\pm$RT and RT$\pm$CT. RT$\pm$CT is judged to be an alternative option that can avoid the functional disability after surgical resection.

키워드

참고문헌

  1. MizunoGS,DiazRF,FuK,BolesR,FranciscoS.Carcinoma of the tonsillar region. Laryngoscope 1986;96: 240-244
  2. Guay ME, Lavertu P. Tonsillar carcinoma. Eur Arch Otorhinolaryngol 1995;252:259-264
  3. Perez CA, Patel MM, Chao C, et al. Carcinoma of the tonsillar fossa: prognostic factors and long-term therapy outcome. Int J Radiat Oncol Biol Phys 1998;42:1077-1984 https://doi.org/10.1016/S0360-3016(98)00291-0
  4. ArgirisA.Updateonchemoradiotherapyforheadandneck cancer. Curr Opin Oncol 2002;14:323-329 https://doi.org/10.1097/00001622-200205000-00012
  5. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-1324 https://doi.org/10.1200/JCO.1998.16.4.1318
  6. Jeremic B, Shibamoto Y, Milicic B , e t a l . Hyperfractionated radiation therapy with or without concurrent low-dose cisplatin in locally advanced squamous cell carcinoma of the headandneck:aprospectiverandomized t r i a l . J C l i n Oncol 2000;18: 1458-1464
  7. TehBS,MongaU,ThornbyJ,GressotL,Parke RB, Donovan DT. Concurrent chemotherapy and concomitant boost radiotherapy forunresectable head a n d n e c k c a n cer. Am J Otolaryngol 2000;21:306-311
  8. Nah BS, Nam TK, Ahn SJ, Chung WK. Results of con - ventional radiotherapy of the tonsillar region. J Korean Soc Ther Radiol 1997;15(2):97-103
  9. Kokubo M, Nagata Y, Nishimura Y, et al. Concurrent chemoradiotherapy for oropharyangeal carcinoma. Am J Clin Oncol 2001;24:71-76 https://doi.org/10.1097/00000421-200102000-00013
  10. Denis F , G a r a u d P , B a r d e t E , e t a l . L a t e t o x i c i t y r e s u l t s o f the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced- stage oropharynx carcinoma: comparison of LENT/ SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003;55:93-98
  11. BradleyPJ.Managementofsquamouscellcarcinomaofthe oropharynx. Curr Opin in Otolaryngol Head Neck Surg 2000;8: 80-86 https://doi.org/10.1097/00020840-200004000-00002
  12. HicksWLJr,KuriakoseMA,LoreeTR,etal.Surgeryversus radiation therapy assingle-modality treatmentof tonsillar fossa carcinoma: the Roswell Park Cancer Institute experience (1991-1991).Laryngoscope1998;108:1014-1019
  13. ParsonsJT,MendenhallWM,Stringer SP, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 2002;94:2967-2980 https://doi.org/10.1002/cncr.10567
  14. Wang MB, Kuber N, Kerner MM, Lee SP, Juilliard GF, Abemayor E. Tonsillar carcinoma: analysis of treatment results. J Otolaryngol 1998;27:263-269
  15. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-955 https://doi.org/10.1016/S0140-6736(00)90011-4
  16. Brizel DM, Albers ME, Grant WH, et al. Hyperfractionated irradiation with orwithout concurrent chemoradiotherapy for locallyadvancedheadandneck cancer. N Eng K Med 1998; 338:1798-1804 https://doi.org/10.1056/NEJM199806183382503
  17. Adelstein DJ, Adams GL,Wagner H, et al. An intergroup phase IIIcomparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamouscell head and neck cancer. J Clin Oncol 2003;21:92-98 https://doi.org/10.1200/JCO.2003.01.008
  18. Jackson SM, Hay JH, Flores AD, et al. Cancer of the tonsil: the results of ipsilateral radiation treatment. Ra diother Oncol 1999;51:123-128 https://doi.org/10.1016/S0167-8140(99)00051-1
  19. O$^'$Sullivan B, W a r de P, Grice B, et al. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 2001;51:332-343
  20. KageiK, Shirato H, Nishioka T, et al. Ipsilateral irradiation forcarcinomasoftonsillarregionandsoftpalatebasedon computed tomographic simulation. Radiotherapy and Oncology 2000;54:117-121 https://doi.org/10.1016/S0167-8140(99)00179-6
  21. Lusinchi A,Wibault P, Marandas P, Kunkler I, Eschwege F. Exclusive radiation therapy: the treatment of early tonsillar tumors. Int J Radiat Oncol Biol Phys 1989;17:273-277 https://doi.org/10.1016/0360-3016(89)90439-2